Y-Intercept (HK)’s Agile Therapeutics AGRX Stock Holding History

Y-Intercept (HK)’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9	Closed	-$24K	–	987
2021 Q2	$24K	Buy	+9	New	+$29.7K	0.01%	579

Other funds holding AGRX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Y-Intercept (HK)'s AGRX Position: Q3 2021 in Review

Y-Intercept (HK) sold out of Agile Therapeutics (AGRX) in Q3 2021, closing a stake of 9 shares — an estimated $24K sold.

Y-Intercept (HK) first reported a position in AGRX in Q2 2021 and held it in 1 quarter. The position peaked at $24K in Q2 2021. 49 funds tracked by Wall St. Rank hold AGRX as of Q3 2021.

Y-Intercept (HK) reported no remaining Agile Therapeutics position as of Q3 2021 after selling out during the quarter.
Y-Intercept (HK) sold 9 Agile Therapeutics shares in Q3 2021, an estimated $24K.
Y-Intercept (HK) first reported a position in Agile Therapeutics in Q2 2021 and held it in 1 quarter.
Y-Intercept (HK)'s Agile Therapeutics position peaked at $24K in Q2 2021.
49 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2021.

Based on Y-Intercept (HK)'s 13F filing for Q3 2021, filed 15 Nov 2021.